Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
1,502 results
  • Obesity: the New Global Epidemic. Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. [Journal Article]
    Endocr Metab Immune Disord Drug Targets. 2020 May 15 [Online ahead of print]Milano W, De Biasio V, … Capasso A
  • CONCLUSIONS: The drugs, associated with the standard diet and / or exercise protocols, represent a good therapeutic opportunity to allow not only weight loss but also to reduce the risk of developing diseases caused by obesity, particularly cardiovascular diseases, and to maintain the set objectives over time. However, future research on the pharmacological treatment of obesity should encourage greater personalization of therapy, given the differences in safety, efficacy and response to therapy, in the different subpopulations of patients with obesity.
  • Obesity: Pharmacotherapy. [Journal Article]
    FP Essent. 2020 May; 492:25-29.Powell A
  • Pharmacotherapy, adjunctively with lifestyle interventions, is an option for any patient diagnosed with obesity (ie, body mass index [BMI] of 30 kg/m2 or greater) or with a BMI of 27 kg/m2 or greater and at least one coexisting condition, including type 2 diabetes, hypertension, hyperlipidemia, and sleep apnea. If the appropriate criteria are met, pharmacotherapy should be initiated for patients …
  • Current Long-Term Pharmacotherapies for the Management of Obesity. [Review]
    J Obes Metab Syndr. 2020 Jun 30; 29(2):99-109.Kim BY, Kang SM, … Committee of Clinical Practice Guidelines, Korean Society for the Study of Obesity (KSSO)
  • Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes mellitus, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight reduction in obese patients wit…
  • The limits and challenges of antiobesity pharmacotherapy. [Journal Article]
    Expert Opin Pharmacother. 2020 Apr 15 [Online ahead of print]Gadde KM, Atkins KD
  • Introduction: Pharmacotherapy is a useful adjunct when patients with obesity are unable to achieve adequate benefit from lifestyle interventions.Areas covered: This review covers the history of antiobesity drugs, efficacy, and risks of currently approved drugs, limits of their usefulness in clinical practice, gaps in knowledge, methodological limitations of clinical trials, and reasons for underu…
  • Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review. [Review]
    World J Mens Health. 2020 Mar 09 [Online ahead of print]Tak YJ, Lee SY
  • As a chronic and relapsing disease, obesity negatively impacts the health of men to a greater extent than that of women, with a higher risk of cardiovascular disease. Since lifestyle modifications alone are often challenging and limited for the maintenance of weight reduction, pharmacotherapy should be considered in a timely manner for obese men or overweight patients with weight-related comorbid…
  • Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review. [Journal Article]
    Front Endocrinol (Lausanne). 2020; 11:70.Pan CS, Stanley TL
  • Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity in individuals with obesity. Although multiple pharmacotherapeutics are in development, currently there are limited strategies specifically targeting NAFLD. This systematic review summarizes the existing literature on hepatic effects of medications used for weight loss. Glucagon-like peptide 1 (GLP-1) agonists are the best-studied …
  • Is There a Prescription to Treat Pediatric Obesity? [Journal Article]
    Am J Lifestyle Med. 2020 Jan-Feb; 14(1):36-39.Srivastava SB
  • Pediatric obesity is complex-in every way. The pathogenesis, which is a result of a multitude of factors combined with social and environmental factors makes it a crisis with overwhelming challenges. It is difficult to treat pediatric obesity; however, guidelines attempt to clarify how to approach treatment. These strategies are mostly interventions in lifestyle because only 1 medication is appro…
  • Phentermine Use During First and Second Trimesters Associated with Fetal Stroke. [Case Reports]
    Cureus. 2019 Nov 16; 11(11):e6170.D'Adesky N, Ghosh S
  • Phentermine is a sympathomimetic amine used for the short-term weight loss that has been associated with ischemic and hemorrhagic strokes in adults. The effects of this medication on a developing fetus are not well studied. We present the case of a woman who was taking phentermine during the first two trimesters of pregnancy and subsequently delivered a child with bilateral porencephalic cysts li…
  • Anorectic state of obesity medications in the United States. Are leaner times ahead? [Review]
    Expert Opin Pharmacother. 2020 Feb; 21(2):167-172.Li X, Bello NT
  • Introduction: Obesity is considered to be a chronic disease. Currently there are five prescription-only medications on the US market for the long-term management of obesity. However, these medications are underutilized by obese or overweight individuals seeking medical assistance for weight management.Areas covered: This special report provides an overview of the emerging obesity pharmacotherapie…
  • A Medical Review of Fatal High-G U.S. Aerobatic Accidents. [Journal Article]
    Aerosp Med Hum Perform. 2019 Nov 01; 90(11):959-965.Mills WD, Greenhaw RM, Wang JMP
  • INTRODUCTION: Exposure to high G force is a known safety hazard in military aviation as well as civilian aerobatic flight. Tolerance to high G forces has been well studied in military pilots, but there is little research directed at civilian pilots who may have medications or medical conditions not permitted in military pilots.METHODS: In this case-control study, we identified 89 fatal high-G a…
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Phentermine-Topiramate [BOOK]
    . National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • The fixed combination of phentermine and topiramate has been developed as a weight loss agent and was approved for use in the United States in 2012. This combination has not been linked to serum enzyme elevations or clinically apparent liver injury, but has had limited general use. Topiramate by itself is used as an anticonvulsant and has been implicated in rare instances of acute liver injury.
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Weight Loss Agents [BOOK]
    . National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • While many agents have been developed to aid in weight loss, few have withstood critical assessment of safety and efficacy. Weight loss agents are held to a high standard for safety and tolerability, because they are often used by otherwise healthy individuals driven more by concerns over appearance than health. Furthermore, all weight loss medications should be used as a part of a coordinated we…
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury: Phentermine [BOOK]
    . National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD)BOOK
  • Phentermine is a sympathomimetic amine and anorectic agent used for the short term therapy of obesity. Phentermine which has been in clinical use for more than 50 years has not been linked convincingly to either serum enzyme elevations during therapy or to instances of clinically apparent liver injury.
New Search Next